Analysis of G1/S checkpoint regulators in metastatic melanoma

We have analyzed the expression of the CDKN1A (p21CIP1), CDKN1B (p27Kip1), TP53, RB1 and MDM2 proteins and tumor cell proliferation by immunohistochemical staining in 59 cases of metastatic melanoma. The genomic status of the CDKN2A (INK4‐ARF, p16/p14ARF), CDKN2B (p15) and CDKN2C (p18) genes was determined by PCR‐SSCP (single‐strand conformation polymorphism) in 46 of these cases. These results were correlated with various clinico‐pathological parameters, including the outcome of combined chemoimmunotherapy. We found positive correlations between the expression of CDKN1A and MDM2 (r = 0.5063, P = 0.001), between the expression of CDKN1B and RB1 (r = 0.5026, P = 0.001), and between RB1 expression and tumor cell proliferation (0.5564, P < 0.001). Two mutations in the CDKN2A (p16) gene were detected, including a novel base change AAC→ATC (Asn to Ile) at codon 71, that also changes the codon 85 of the alternative reading frame gene p14ARF from CAA to CAT (Gln to His). Homozygous deletion at exon 2 of the CDKN2A (INK4‐ARF) gene was detected in six cases. In seven cases, the 540C→G polymorphism in the 3′UTR of the CDKN2A (p16) gene was found in linkage disequilibrium with the 74C→A polymorphism in intron 1 of the CDKN2B gene (P < 0.0001). These cases had significantly lower expression of the TP53 protein (P = 0.0032). Both 540C→G and 580C→T polymorphisms in the 3′UTR of the CDKN2A (p16) gene were associated with significantly shorter progression time from primary to metastatic disease (P = 0.0071). We conclude, that although none of the analyzed cell cycle regulators could be singled out as a major prognostic factor, G1/S checkpoint abnormalities remain one of the most significant factors in the development of malignant melanoma. Genes Chromosomes Cancer 28:404–414, 2000. © 2000 Wiley‐Liss, Inc.

[1]  E. Medrano,et al.  High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. , 1999, The Journal of investigative dermatology.

[2]  H. Kerl,et al.  UV fingerprint CDKN2a but no p14ARF mutations in sporadic melanomas. , 1999, The Journal of investigative dermatology.

[3]  Y. Xiong,et al.  Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. , 1999, Molecular cell.

[4]  K. Hemminki,et al.  Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. , 1999, Melanoma research.

[5]  S. Cowper,et al.  Expression of p-27 (kip1) in nevi and melanomas. , 1999, The American Journal of dermatopathology.

[6]  D. Duffy,et al.  CDKN2A variants in a population-based sample of Queensland families with melanoma. , 1999, Journal of the National Cancer Institute.

[7]  S. Zerp,et al.  p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis , 1999, British Journal of Cancer.

[8]  David Hogg,et al.  Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma , 1999, Nature Genetics.

[9]  Rajiv Kumar,et al.  Selective deletion of exon 1β of the p19ARF gene in metastatic melanoma cell lines , 1998, Genes, chromosomes & cancer.

[10]  G. Peters,et al.  The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.

[11]  C. Sherr,et al.  Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.

[12]  D. Whiteman,et al.  p53 expression and risk factors for cutaneous melanoma: A case‐control study , 1998, International journal of cancer.

[13]  D. Wong,et al.  p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma , 1998, Journal of cutaneous pathology.

[14]  D. English,et al.  p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. , 1998, The American Journal of dermatopathology.

[15]  G. Wilson,et al.  An analysis of p16 protein expression in sporadic malignant melanoma , 1998, Melanoma research.

[16]  G. Walker,et al.  Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets , 1998, Genes, chromosomes & cancer.

[17]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[18]  D. Stoppa-Lyonnet,et al.  Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. , 1998, Human molecular genetics.

[19]  K. Hemminki,et al.  Mutations in the CDKN2A ( p16INK4a ) gene in microdissected sporadic primary melanomas , 1998, International journal of cancer.

[20]  J. Hansson,et al.  Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study. , 1998, International journal of cancer.

[21]  N. Hayward,et al.  Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. , 1997, Cancer research.

[22]  S. H. Kim,et al.  Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. , 1997, Biochemical and biophysical research communications.

[23]  Y. Collan,et al.  Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage , 1997, International journal of cancer.

[24]  V. Tron,et al.  Overexpression of the cyclin‐dependent kinase inhibitor p21WAF1/GIP1 in human cutaneous malignant melanoma , 1997, Journal of cutaneous pathology.

[25]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[26]  A. Hartmann,et al.  Overexpression and mutations of p53 in metastatic malignant melanomas , 1996, International journal of cancer.

[27]  J. Zitelli,et al.  Favorable prognostic factors in recurrent and metastatic melanoma. , 1996, Journal of the American Academy of Dermatology.

[28]  Y. Collan,et al.  Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin. , 1996, Pathology, research and practice.

[29]  M. Skolnick,et al.  CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. , 1995, Oncogene.

[30]  C. Shea,et al.  Immunohistochemical expression of retinoblastoma protein in cutaneous melanomas , 1995, The British journal of dermatology.

[31]  D. English,et al.  Prognostic significance of p53 over‐expression in thin melanomas , 1995, Melanoma research.

[32]  A. Albino,et al.  Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. , 1995, Cancer research.

[33]  P. Pollock,et al.  Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. , 1995, Oncogene.

[34]  C. Saenz‐Santamaría,et al.  p53 Expression Is Rare in Cutaneous Melanomas , 1995, The American Journal of dermatopathology.

[35]  S. Pyrhönen,et al.  Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy , 1995, The British journal of dermatology.

[36]  B. Iacopetta,et al.  p53 gene mutation and expression in naevi and melanomas , 1995, Melanoma research.

[37]  C. Poremba,et al.  Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. , 1995, Oncology research.

[38]  S. Pyrhönen,et al.  A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.